Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04326673
Other study ID # 2020LAB110
Secondary ID
Status Completed
Phase
First received
Last updated
Start date October 30, 2020
Est. completion date October 30, 2023

Study information

Verified date May 2024
Source The Royal Wolverhampton Hospitals NHS Trust
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The purpose is to evaluate Sal-T against standard biomarkers of male gonadal status based on serum T, calculated free T and BAT. The optimal salivary sampling in terms of fasting and time of day will also be defined. The ultimate aim is to add Sal-T into the Trust's repertoire of tests in investigating suspected hypogonadism in men.


Description:

To investigate whether salivary (free) testosterone is subject to similar prandial variations reported for serum total testosterone. Study 1: Assessment of diurnal variation in salivary testosterone adjusted for prandial state in 20 healthy men. Study 2: Measurement of salivary and serum testosterone and related biomarkers before and after a standard 75g oral glucose load in 40 men.


Recruitment information / eligibility

Status Completed
Enrollment 40
Est. completion date October 30, 2023
Est. primary completion date October 30, 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Male
Age group 20 Years to 60 Years
Eligibility For 1st part of study -volunteers: Inclusion Criteria: - Aged 20-60 years - Male Exclusion Criteria: - Subjects with learning disability or those lacking mental capacity to give consent. - On (prescribed and over-the-counter) medication and herbal remedies known to affect androgen metabolism. - Known hypogonadism. - Conditions known to affect androgen metabolism, including chronic inflammatory diseases, chronic liver disease, chronic kidney disease and thyroid dysfunction. - Any co-morbidity. - Periodontal disease. - Dental work 48 hours prior to the test. - Exercise on the day, prior to and during sampling periods. - Brushed teeth within 1hr prior to sample collection. - Obesity defined as a body mass index (BMI) of greater than 29.9 kg/m2As 2nd part of study for glucose load - oral glucose tolerance test (OGTT): Inclusion criteria: - Aged over 40-60 years. - Attending for routine 75 g OGTT Exclusion criteria: - Subjects with learning disability or lacking mental capacity to give consent. - On (prescribed and over-the-counter) medication and herbal remedies known to affect androgen metabolism. - Known hypogonadism. - Conditions known to affect androgen metabolism, including chronic inflammatory diseases, chronic liver disease, chronic kidney disease and thyroid dysfunction. - Subjects with difficult venous access. - Periodontal disease. - Dental work 48 hours prior to the test. - Brushed teeth within 1hour prior to sample collection. - Exercise on day prior to and during the OGTT.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Testosterone Measurements in healthy volunteers after fasting
salivary testosterone measurements taken in morning and evening and a single blood test for testosterone taken
Testosterone Measurements after glucose loading
salivary tstosterone and blood testosterone measurements

Locations

Country Name City State
United Kingdom The Royal Wolverhampton NHS Trust Wolverhampton West Midlands

Sponsors (1)

Lead Sponsor Collaborator
The Royal Wolverhampton Hospitals NHS Trust

Country where clinical trial is conducted

United Kingdom, 

References & Publications (1)

Fenn J, Gill H, Starbrook L, Ford LT, Sharrod-Cole H, Kalaria T, Ford C, Gama R. Salivary testosterone changes during oral glucose tolerance tests in overweight and obese men - postprandial or circadian variation? Ann Clin Biochem. 2024 Apr 9:456322412490 — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Changes in salivary testosterone during the day independent of prandial state testosterone levels 24 hours
Primary Changes in salivary testosterone following an oral glucose load testosterone levels 2 hours
See also
  Status Clinical Trial Phase
Completed NCT04467697 - Ambulatory Blood Pressure Monitoring (ABPM) Extension Study of Oral Testosterone Undecanoate in Hypogonadal Men Phase 3
Completed NCT03203681 - Natesto Effects on Testosterone, Luteinizing Hormone, Follicle Stimulating Hormone and Semen Parameters Phase 4
Completed NCT01904734 - Clomid in Men With Low Testosterone With and Without Prior Treatment Phase 2
Completed NCT00398580 - 28-Day Study of Testosterone Co-administered With Dutasteride in Hypogonadal Men Phase 2
Completed NCT00400335 - Study On Bioavailability And Pharmacokinetics Of Various Doses Of Testosterone Administered With And Without Dutasteride Phase 1
Recruiting NCT05611307 - Late Subclinical Cardiovascular Disease in Testicular Cancer Survivors
Completed NCT03282682 - Strength Training as a Supplemental Therapy of Androgen Deficiency of the Aging Male N/A
Terminated NCT03335254 - A Phase 1/2a Study to Determine the Dose Response Pharmacokinetics of TSX-011 (Testosterone Undecanoate) in Hypogonadal Males Phase 1/Phase 2
Terminated NCT05205837 - A Randomized, Double-blinded, Clinical, Placebo-controlled Trial on the Effects of Therapy With Letrozole and hUman Choriongonadotropin in Male Hypogonadism Induced by Illicit Use of Anabolic Androgenic Steroids- The LUCAS Trial Phase 4
Completed NCT03747003 - Gonadal Function in Young to Middle Aged HIV-infected Men
Withdrawn NCT03176537 - Periodontal Profile of Hypogonadic Men Phase 4
Recruiting NCT04049331 - Testosterone Replacement in Male Cancer Survivors With Fatigue and Low Testosterone Phase 2
Completed NCT03541395 - Testosterone-Dependent Effects on Protein Biomarkers From Healthy Males N/A
Recruiting NCT05249634 - Testosterone Treatment in Men With Chronic Kidney Disease Phase 2
Not yet recruiting NCT05773183 - Exploring the Relationship Between Androgen Metabolism, Metabolic Disease and Skeletal Muscle Energy Balance in Men
Withdrawn NCT04717362 - The Effects of Natesto For Treatment Of Hypogonadism Early Phase 1
Completed NCT05806723 - Effects of High Intensity Statin Therapy on Steroid Hormones and Vitamin D in Type 2 Diabetic Men Phase 4
Completed NCT04456296 - A Study of the Effect of Testosterone Replacement Therapy on Blood Pressure in Adult Male Participants With Hypogonadism Phase 4
Not yet recruiting NCT06312761 - Single-Dose Pharmacokinetics of Oral Testosterone Undecanoate With and Without Concomitant Inhibition of UGT2B17 Phase 1/Phase 2
Recruiting NCT05381831 - Natesto Spermatogenesis Reboot Phase 4